// App-Quantinova.ai

PO‐214 : Pegylated filgrastim compared to filgrastim for stem cell mobilization in multiple myeloma

Researchers

Presenter

  • MB Abid

Principal Investigators

  • S De Mel

  • ES Yap

  • MA Abid

  • HC Wong

  • SK Gopalakrishnan

  • Y Chen

  • WJ Chng

  • LK Tan

Medical Centers

  • Haematology & Stem Cell Transplantation, Bristol Haematology Oncology Center (BHOC), Bristol NHS Trust, Bristol, United Kingdom

  • Haematology & Stem Cell Transplantation, National University Cancer Institute Singapore, Singapore, Singapore

  • John Hopkins School of Medicine, Baltimore MD USA, Baltimore, United States

  • Department of Biostatistics & Epidemiology, Saw Swee Hok School of Public Health, National University of Singapore (NUS)

  • Haematology & Stem Cell Transplantation, Singapore General Hospital, Singapore, Singapore

Locations

  • United Kingdom

  • Singapore

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Cluster of Differentiation 34

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Pegfilgrastim

  • Vinorelbine

  • Thalidomide

  • Bortezomib

  • Filgrastim

  • Melphalan

Outcome

  • N/A

Study Design

  • Randomized

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved